Amersham focuses on cost management with software
This article was originally published in Clinica
Executive Summary
Amersham Health is launching software that will give healthcare providers tighter control over myocardial perfusion imaging costs. The product will enable nuclear cardiologists to make more informed decisions, Amersham Health says. The software provides managers with a means of analysing costs in a number of categories, including labour, capital equipment, facility, pharmaceuticals and supplies.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.